Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study discusses a hypothesis that combining intermittent androgen ablation therapy with finasteride may enhance prostate cancer treatment, though new results from this approach are not yet available.

This study found that dutasteride effectively improves symptoms of benign prostatic hyperplasia, showing benefits in urinary flow and quality of life, with only modestly elevated sexual side effects compared to placebo.

This Cochrane review reports that 5-alpha reductase inhibitors may slightly reduce urological symptoms and acute urinary retention risk compared to placebo, with a possible small reduction in surgical intervention need compared to alpha blockers.

This study will explore whether combination therapy with either dutasteride or finasteride and an α1 blocker is more effective than monotherapy for treating BPH, but it reports no new results.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This study found that combining cyproterone acetate with testosterone enanthate was highly effective in suppressing spermatogenesis, suggesting potential as a reversible male contraceptive method.

This study suggests that combining the 5α-reductase inhibitor 4-MA with the antiandrogen Flutamide may improve prostate cancer therapy by additively inhibiting prostatic growth and androgen-sensitive functions in rats.

This article reviews the use of cyproterone acetate for conditions like prostate cancer and sexual disorders, highlighting its effects on libido but reporting no new specific trial results.

This study found that dutasteride effectively improved urinary symptoms, reduced acute urinary retention risk, and decreased prostate volume in men with moderate to severe BPH over two years.

This review found dutasteride to be effective, safe, and well-tolerated for treating symptomatic BPH and provides expert commentary on its use, though the relationship with high-grade prostate cancer remains unclear.

This study found that dutasteride significantly reduces the risk of acute urinary retention and surgical intervention in men with benign prostatic enlargement compared to placebo.

This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.

This review analyzes existing literature on prognostic factors for renal cell carcinoma, highlighting the need for continuous updates of prognostic models to reflect advancement in molecular pathway knowledge and targeted therapies.

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.

Dutasteride reduces DHT more effectively than finasteride.

This article discusses the newly approved drug dutasteride for managing benign prostatic hyperplasia, but reports no new research findings; the authors advise obtaining complete information before prescribing.

This study observed that long-term treatment with 5ARIs in men with LUTS/BPH was linked to worsening sexual function, whereas doxazosin alone had minimal negative impact.

Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.

This study in rats suggests that combining the 5 alpha-reductase inhibitor 4-MA with the antiandrogen Flutamide may enhance prostate cancer therapy by additively inhibiting prostatic growth and mRNA levels of androgen-sensitive prostatic binding proteins.

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.

This study demonstrated that testosterone treatment increases muscle strength and alters body composition in transmen, and the addition of dutasteride does not impair these anabolic effects.

This article reviews the use of 5alpha-reductase inhibitors for managing benign prostatic hyperplasia and reports no new clinical results.

This study found that overexpression of AKR1C3 in prostate cancer cells redirected androgen metabolism towards testosterone production, which facilitated cell proliferation, potentially reducing the effectiveness of finasteride treatment.